Stocks and Investing Stocks and Investing
Fri, September 15, 2023
Thu, September 14, 2023

Paul Matteis Reiterated (ALNY) at Strong Buy and Held Target at $240 on, Sep 14th, 2023


Published on 2024-10-28 06:25:33 - WOPRAI, Paul Matteis
  Print publication without navigation


Paul Matteis of Stifel, Reiterated "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy and Held Target at $240 on, Sep 14th, 2023.

Paul has made no other calls on ALNY in the last 4 months.



There are 5 other peers that have a rating on ALNY. Out of the 5 peers that are also analyzing ALNY, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Reiterated at Hold and Held Target at $210 on, Friday, August 4th, 2023


These are the ratings of the 4 analyists that currently disagree with Paul


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $270 on, Tuesday, September 12th, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $250 on, Tuesday, August 8th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $405 on, Monday, August 7th, 2023
  • David Lebovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $266 on, Friday, August 4th, 2023

Contributing Sources